Insmed Inc.

Address: 700 Us Highway 202/206

Sponsor Overview

assignment

Specializations

Respiratory infection and nontuberculous mycobacterial lung disease

Insmed Inc. supports clinical research in Mycobacterium avium complex-related lung infection, with a strong focus on persistent respiratory symptoms and treatment strategies for adults with newly diagnosed NTM lung infection.

Amikacin Liposome Inhalation Suspension
Macrolide-based background therapy
Ethambutol-containing regimens

The sponsor’s work in this area centers on inhaled anti-infective approaches and symptom relief in chronic pulmonary infection.

Chronic airway inflammation and sinonasal disease

Clinical studies include chronic rhinosinusitis without nasal polyps, with attention to nasal congestion, sinonasal symptoms, and inflammatory control in adults with persistent upper airway disease.

Brensocatib
Upper airway inflammation
Symptom improvement

This area reflects interest in noninfectious inflammatory disorders affecting the nose and sinuses.

Hidradenitis suppurativa and neutrophil-driven inflammation

Insmed Inc. is active in research on hidradenitis suppurativa, a chronic inflammatory skin condition marked by recurrent lesions and ongoing disease burden.

Brensocatib
Moderate to severe disease
Inflammatory skin disease

The therapeutic focus in this field is on controlling cutaneous inflammation and improving disease symptoms in affected adults.

Pulmonary arterial hypertension

The sponsor funds studies in pulmonary arterial hypertension, with emphasis on pulmonary vascular resistance, exercise capacity, and long-term disease management in patients with advanced cardiopulmonary impairment.

Treprostinil Palmitil Inhalation Powder
Inhaled prostacyclin therapy
Cardiopulmonary function

These trials address vascular and functional outcomes in a chronic pulmonary vascular disorder.

Pulmonary hypertension associated with interstitial lung disease

Research also extends to pulmonary hypertension associated with interstitial lung disease, a condition combining progressive lung fibrosis with elevated pulmonary pressure and impaired breathing.

Treprostinil Palmitil Inhalation Powder
Interstitial lung disease
Respiratory and vascular symptoms

The sponsor’s interest in this area centers on inhaled therapy for patients with overlapping parenchymal lung disease and pulmonary hypertension.

Sponsored Trials

Trial Name	Country	Status
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps – The BiRCh Study	Belgium Bulgaria Czechia Denmark France Germany Hungary Italy Poland Portugal Spain	Not Recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease	Austria Belgium Czechia Denmark France Germany Greece Italy Poland Portugal Romania Spain	Recruiting
Efficacy and Safety Evaluation of Amikacin Liposome Inhalation Suspension with Azithromycin and Ethambutol in Adult Patients with MAC-Induced NTM Lung Infection	Austria Belgium Denmark France Germany Greece Hungary Italy Poland Portugal Spain	Not Recruiting
Efficacy and Safety Evaluation of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa: A Randomized, Double-Blind, Placebo-Controlled Study	Bulgaria France Germany Greece Poland Spain The Netherlands	Not Recruiting
Evaluation of Long-Term Safety and Efficacy of Treprostinil Palmitil Inhalation Powder in Pulmonary Hypertension Associated with Interstitial Lung Disease	Belgium Germany Italy Spain	Not Recruiting
Evaluation of Long-Term Safety, Tolerability, and Efficacy of Treprostinil Palmitil Inhalation Powder in Pulmonary Arterial Hypertension Patients	Austria Belgium Denmark Germany Italy Spain	Not Recruiting
Evaluation of Treprostinil Palmitil Inhalation Powder on Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study	Austria Belgium Denmark Germany Italy Spain	Not Recruiting
Open-Label Extension Study of Inhaled Treprostinil Palmitil Powder for Safety and Tolerability in Pulmonary Hypertension Associated with Interstitial Lung Disease	Austria Belgium Czechia Denmark France Germany Greece Italy Poland Portugal Romania Spain	Not Yet Recruiting